Evidence map›Paper›PMID 38295282›Full record

ArticleBlood advances2024

Autophagy prevents graft failure during murine graft-versus-host disease.

Katie E Lineburg, Lucie Leveque-El Mouttie, Christopher R Hunter, Laetitia Le Texier, Crystal McGirr, Bianca Teal, Bruce R Blazar, Steven W Lane, Geoffrey R Hill, Jean-Pierre Lévesque and 1 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Better eat!Blood advances · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Katie E LineburgDepartment of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0002-5712-2610
Lucie Leveque-El MouttieDepartment of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Christopher R HunterDepartment of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Laetitia Le TexierDepartment of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Crystal McGirrStem Cell Biology Group, Mater Research Institute, The University of Queensland, Brisbane, Australia.
Bianca TealDepartment of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Bruce R BlazarPediatric Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-9608-9841
Steven W LaneDepartment of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0002-8050-6209
Geoffrey R HillTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Jean-Pierre LévesqueStem Cell Biology Group, Mater Research Institute, The University of Queensland, Brisbane, Australia.
Kelli P A MacDonaldDepartment of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
QIMR Berghofer Medical Research Institute · AUThe University of Queensland · AUUniversity of Minnesota · USUniversity of Washington · US

Funding

Single Cell Analysis and ImmunogeneticsP01HL158505 · NHLBI · DANA-FARBER CANCER INST · PI Corey S Cutler · 2022 to 2026
$15.3M
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory DiseaseR01HL155114 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, NOELLE, RANDOLPH J. · 2021 to 2024
$2.7M
NHLBI NIH HHS P01 HL158505NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL095791NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL147324NHLBI NIH HHS R01 HL155114NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

abstractAutophagy is an intracellular survival process that has established roles in the long-term survival and function of hematopoietic stem cells (HSC). We investigated the contribution of autophagy to HSC fitness during allogeneic transplantation and graft-versus-host disease (GVHD). We demonstrate in vitro that both tumor necrosis factor and IL-1β, major components of GVHD cytokine storm, synergistically promote autophagy in both HSC and their more mature hematopoietic progenitor cells (HPC). In vivo we demonstrate that autophagy is increased in donor HSC and HPC during GVHD. Competitive transplant experiments demonstrated that autophagy-deficient cells display reduced capacity to reconstitute the hematopoietic system compared to wild-type counterparts. In a major histocompatibility complex-mismatched model of GVHD and associated cytokine dysregulation, we demonstrate that autophagy-deficient HSC and progenitors fail to establish durable hematopoiesis, leading to primary graft failure and universal transplant related mortality. Using several different models, we confirm that autophagy activity is increased in early progenitor and HSC populations in the presence of T-cell-derived inflammatory cytokines and that these HSC populations require autophagy to survive. Thus, autophagy serves as a key survival mechanism in HSC and progenitor populations after allogeneic stem cell transplant and may represent a therapeutic target to prevent graft failure during GVHD.

Indexed as

AutophagyGraft vs Host DiseaseHematopoietic Stem Cell TransplantationAnimalsCytokinesDisease Models, AnimalGraft RejectionHematopoietic Stem CellsMiceTransplantation, HomologousCytokines

Identifiers

PMID38295282
PMCPMC11103170
OpenAlexW4391377236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.